Phase 2a Study of HPG1860 in Subjects With NASH

Inclusion Criteria: 1. Provision of written informed consent prior to any study-specific procedure. 2. Males and females between 18 and 75 years of age 3. Nonpregnant, nonlactating women. 4. Male subjects must agree to utilize a highly effective method of contraception. 5. Body mass index (BMI) of ≥25 kg/m2 at Screening. 6. Non-cirrhotic NASH subjects. 7. NASH subjects with hepatic fat assessed by a central reader 8. Willing and able to adhere to study restrictions and agree to comply with study protocol. Exclusion Criteria: 1. Pregnant or lactating females 2. Current significant alcohol consumption 3. Elevated LDL-C with stable dose of statin an or PCSK9 inhibitor 4. Renal dysfunction or nephritic syndrome or a history of nephritis 5. Recent infarction, unstable angina leading to hospitalization, uncontrolled, symptomatic cardiac arrhythmia 6. Uncontrolled hypertension 7. Type 1 diabetes or uncontrolled T2DM 8. Uncontrolled hypothyroidism 9. Liver transplant and/or other significant liver disease or dysfunction 10. HIV antibody positive 11. Known hypersensitivity or formulation excipient 12. Gastrointestinal conditions or procedures that may affect drug absorption 13. Hematologic or coagulation disorders 14. Unstable weight within the last 3 months 15. Active malignancy 16. Unexplained creatine kinase (CK) \>3 × ULN 17. Blood donation, blood transfusion 18. Unable to undergo or contraindication to MRI procedure 19. A medical or situational finding that in the investigator's opinion may compromise the subject's safety or ability to complete the study.